Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news


From To
TAC: ARV treatment education best way to bring down HIV infection rates

An activist organisation, the Treatment Action Campaign (TAC), says that for South Africa to further decrease the rate of new HIV infections more needs to be done to curb treatment defaulting for persons on the ARV treatment programme.

18 July 2018
Eyewitness News
Blood, Hair, or Urine? Weighing PrEP Adherence Options Beyond Self-Report

Understanding whether a person with a PrEP prescription is actually using the medication is something a provider may want to know. Currently, a few measures determine adherence to PrEP: self-report, hair, dried blood spot, and urine analysis. As of now, no one guideline or definitive standard is being used. Clinicians and researchers presented their recent findings at the 13th Annual Adherence Conference last month in Miami.

16 July 2018
The Body Pro
'Emotional closeness’ key to successful HIV treatment support

The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.

15 June 2018
Is the World Ready for Long-Acting HIV Treatment?

"As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

11 June 2018
The Body Pro
Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

Short cycle therapy (SCT) comprising an antiretroviral therapy (ART) regime of 5 days on and 2 off achieved sustainable noninferiority of virological suppression in young people with HIV compared with continuous therapy (CT) over a median of 3.6 years, according to research published in PLos One.

25 May 2018
Infectious Disease Advisor
Smartphone app keeps an 'eye' on daily tuberculosis therapy

Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits.

27 April 2018
Eurekalert Inf Dis
Has Anyone Gotten HIV When They Were on PrEP?

At least 300,000 individuals are now using PrEP worldwide, and only two incidents have been reported where individuals with verified adherence to the drug acquired HIV. Three additional cases have been reported with unconfirmed adherence, and three are currently under investigation.

22 April 2018
The Body
Uganda:HIV Patients to Get Rewards for Taking ARVs

Mildmay Uganda and the United States based RAND Corporation yesterday launched a five-year research study of rewarding people living with HIV who take their antiretroviral drugs consistently.

20 April 2018
Researchers ID four types of nonbiomedical PrEP failure

Serota and colleagues describe 14 men who became infected with HIV in their EleMENt study of 300 young BMSM in Atlanta, despite being offered PrEP, along with services to ease access to PrEP uptake. They rightly point out that, in addition to the rare biomedical PrEP failures that receive so much attention at scientific meetings, we should focus our attention on the other “typologies” of PrEP failure that occur once PrEP is offered: low PrEP adherence, PrEP discontinuation, PrEP contemplation without initiation and PrEP refusal.

14 April 2018
ARV stock-outs kill more Ugandans

“Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

12 April 2018
The Observer
← First12345...41Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.